Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3406]

NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear cell RCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Status of anti BCMA therapy in myeloma

Dr Dibakar Podder - Tata Medical Center, Kolkata, India

Status of anti BCMA therapy in myeloma ( Dr Dibakar Podder - Tata Medical Center, Kolkata, India )

The promise of CAR T cell therapy for multiple myeloma

Dr Dibakar Podder - Tata Medical Center, Kolkata, India

The promise of CAR T cell therapy for multiple myeloma ( Dr Dibakar Podder - Tata Medical Center, Kolkata, India )

Linvoseltamab can be a potentially effective treatment option for patients with...

Dr Suzanne Lentzsch - Columbia University, New York, USA

$Linvoseltamab can be a potentially effective treatment option for patients with relapsed/refractory multiple myeloma ( Dr Suzanne Lentzsch - Columbia University, New York, USA )$

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

The combination of regorafenib, nivolumab and SCRT shows promising efficacy as...

Dr Francesco Sclafani - Institut Jules Bordet, Brussels, Belgium

The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC ( Dr Francesco Sclafani - Institut Jules Bordet, Brussels, Belgium )

Preview: World Cancer Congress 2024

Union for International Cancer Control

Preview: World Cancer Congress 2024 ( Union for International Cancer Control )

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful...

Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients ( Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea )

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )

Research highlights in gastrointestinal tumours

Dr Jesus Fabregas - Memorial Cancer Institute, Miami, USA

Research highlights in gastrointestinal tumours ( Dr Jesus Fabregas - Memorial Cancer Institute, Miami, USA )

GIST tumours and soft tissue sarcomas

Dr Atif Hussein - Memorial Cancer Institute, Miami, USA

GIST tumours and soft tissue sarcomas ( Dr Atif Hussein - Memorial Cancer Institute, Miami, USA )

More from ecancer